Public health economic evaluation of different European Union-level policy options aimed at reducing population dietary trans fat intake.
The adverse relation between dietary trans fatty acid (TFA) intake and coronary artery disease risk is well established. Many countries in the European Union (EU) and worldwide have implemented different policies to reduce the TFA intake of their populations.



The aim of this study was to assess the added value of EU-level action by estimating the cost-effectiveness of 3 possible EU-level policy measures to reduce population dietary TFA intake. This was calculated against a reference situation of not implementing any EU-level policy (i.e., by assuming only national or self-regulatory measures).



We developed a mathematical model to compare different policy options at the EU level: 1) to do nothing beyond the current state (reference situation), 2) to impose mandatory TFA labeling of prepackaged foods, 3) to seek voluntary agreements toward further reducing industrially produced TFA (iTFA) content in foods, and 4) to impose a legislative limit for iTFA content in foods.



The model indicated that to impose an EU-level legal limit or to make voluntary agreements may, over the course of a lifetime (85 y), avoid the loss of 3.73 and 2.19 million disability-adjusted life-years (DALYs), respectively, and save >51 and 23 billion euros when compared with the reference situation. Implementing mandatory TFA labeling can also avoid the loss of 0.98 million DALYs, but this option incurs more costs than it saves compared with the reference option.



The model indicates that there is added value of an EU-level action, either via a legal limit or through voluntary agreements, with the legal limit option producing the highest additional health benefits. Introducing mandatory TFA labeling for the EU common market may provide some additional health benefits; however, this would likely not be a cost-effective strategy.
European Commission, Joint Research Centre (JRC), Ispra, Italy.
Carlos
0000-0002-3969-6768
C
Martin-Saborido
European Commission, Joint Research Centre (JRC), Ispra, Italy.
Theodora
T
Mouratidou
European Commission, Joint Research Centre (JRC), Ispra, Italy.
Anastasia
A
Livaniou
European Commission, Joint Research Centre (JRC), Ispra, Italy.
Sandra
0000-0002-6057-5979
S
Caldeira
European Commission, Joint Research Centre (JRC), Ispra, Italy jan.wollgast@ec.europa.eu.
Jan
0000-0002-6077-8653
J
Wollgast
D003362:Cost-Benefit Analysis; D005062:European Union; D005260:Female; D005515:Food Labeling; D018857:Food Packaging; D006801:Humans; D008297:Male; D008962:Models, Theoretical; D018673:Nutrition Policy; D011634:Public Health / Q000191:economics*; D019057:Quality-Adjusted Life Years; D044242:Trans Fatty Acids / Q000008:administration & dosage*
D044242:Trans Fatty Acids
European Union; cost-effectiveness; public health; public policy; trans fatty acids
Value Health. 2012 Sep-Oct;15(6):835-42
22999133
BMJ Open. 2012 Sep 17;2(5):null
22986123
Lancet. 2010 Nov 20;376(9754):1775-84
21074255
BMJ. 2011 Jul 28;343:d4044
21798967
Eur J Clin Nutr. 2009 May;63 Suppl 2:S5-21
19424218
Bull World Health Organ. 2013 Apr 1;91(4):262-9H
23599549
Eur J Clin Nutr. 1999 Feb;53(2):143-57
10099948
Bull World Health Organ. 2012 Jul 1;90(7):522-31
22807598
BMJ Open. 2014 May 20;4(5):e005218
24844273
Lancet. 2012 Dec 15;380(9859):2197-223
23245608
BMJ. 2015 Aug 11;351:h3978
26268692
BMJ. 2014 Apr 15;348:g2272
24736206
Value Health. 2012 Sep-Oct;15(6):804-11
22999129
Lancet. 1993 Mar 6;341(8845):581-5
8094827
Nutr Metab Cardiovasc Dis. 2012 Mar;22(3):161-6
22364888
Eur J Clin Nutr. 2013 May;67(5):541-7
23531781
BMJ Open. 2013 Jul 03;3(7):null
23824313
BMJ Open. 2016 Mar 14;6(3):e010673
26975938
World Health Organ Tech Rep Ser. 2003;916:i-viii, 1-149, backcover
12768890
BMJ. 2015 Sep 15;351:h4583
26374614
Am J Prev Med. 2016 Jan;50(1):69-76
26319518
Pharmacoeconomics. 2008;26(9):725-7
18767892
Value Health. 2012 Sep-Oct;15(6):812-20
22999130